WASHINGTON - U.S. pharmaceutical giant Pfizer Inc. and its German partner BioNTech SE said Tuesday they are starting a clinical study to evaluate the safety of an experimental vaccine targeting the new Omicron variant of the coronavirus.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
